Over-expression of epidermal growth factor receptor (EGFR) has been reported in a number of human malignancies. Strong expression of this receptor has been associated with poor survival in many such patients. Active immunizations that elicit antibodies of the desired type could be an appealing alternative to conventional passive immunization. In this regard, a novel recombinant peptide vaccine capable of prophylactic and therapeutic effects was constructed. A novel fusion recombinant peptide base vaccine consisting of L2 domain of murine extra-cellular domain-EGFR and EGFR mimotope (EM-L2) was constructed and its prophylactic and therapeutic effects in a Lewis lung carcinoma mouse (C57/BL6) model evaluated. Constructed recombinant peptide vaccine is capable of reacting with anti-EGFR antibodies. Immunization of mice with EM-L2 peptide resulted in antibody production against EM-L2. The constructed recombinant peptide vaccine reduced tumor growth and increased the survival rate. Designing effective peptide vaccines could be an encouraging strategy in contemporary cancer immunotherapy. Investigating the efficacy of such cancer immunotherapy approaches may open exciting possibilities concerning hyperimmunization, leading to more promising effects on tumor regression and proliferation.
survival rates in these patients. The ECD of EGFR consists of four domains: L1, S1, L2 and S2 (9) . It has been shown that L2 domain plays a major role in ligand binding (10) .
Activation of the EGFR signaling pathway in cancer cells has been shown to enhance cell proliferation, angiogenesis, tumor promotion and metastasis. The potential of EGFR-targeted therapies for cancer has recently led to increased development of different therapeutic agents. Numerous methods, including use of mAbs and small molecule suppressors, have been developed for therapeutic targeting of the EGFR molecule, (11, 12) . A new era of cancer therapy started when the first mAb was unveiled (13) . However, it soon became evident that such approaches could have unforeseen limitations like poor efficacy and limiting side effects because of their passive nature. Given the role of cytotoxic T cells in destruction of cancer cells, T cell-dependent immunity therefore came into focus for several years. These studies showed that tumor antigen identification was directed to those recognized by T cells, and immunotherapy trials sought to induce antigen-specific T cells rather than antibodies (14) . When these studies were not as successful as expected, it was suggested that tumor cells use multiple mechanisms to escape from T cell-mediated immune recognition (15) . Chimeric and humanized mAbs such as trastuzumab showed promising therapeutic results; however, their limitations include the need for repeated administration to achieve effective titers, the elicited antitumor activity and their high price.
Active immunization that can elicit antibodies of the desired type would be an attractive alternative strategy in cancer immunotherapy. Such methods can efficiently stimulate patients' immune systems to eliminate cancer and inhibit its spread (16) . Previously, we mapped ICR-62 (an EGFR mAb) and reported an EGFR mimotope, short peptide molecules mimicking epitope structure, and proved its anti-tumour activity (17, 18) . To design a vaccine candidate capable of inducing a significant humoral immune response, we decided to construct a novel recombinant peptide vaccine, composed of L2 domain of EGFR and the EGFR mimotope (EM-L2). Since bioinformatics tools are currently employed in various aspects of biological studies such as investigating the mechanism and structure of various proteins (19) (20) (21) (22) (23) and vaccine design (24) (25) (26) , we have used these tools to design a EM-L2 recombinant peptide vaccine (18) . Herein, using ectopic Lewis lung carcinoma animal model, we evaluated prophylactic and therapeutic potentials of this new recombinant peptide vaccine.
MATERIALS AND METHODS

Ethics statement
This study was performed in strict accordance with animal use protocols throughout. The mice were anesthetized and then killed by cervical dislocation. All procedures were performed in accordance with the ethical guidelines of the School of Advanced Technologies in Medicine, Tehran University of Medical Sciences. All performed experimental protocols in this study were approved by the Ethical Committee of School of Advanced Technologies in Medicine, Tehran University of Medical Sciences.
ELISA analysis for verification of expressed peptide
The recombinant EM-L2 peptide was expressed and purified using a method reported by Asadi-Ghalehni et al. (18) . One microgram of purified recombinant EM-L2 peptide in 100 mL Na 2 CO 3 /NaHCO 3 buffer was coated into each well of an ELISA plate and incubated at 37°C for 4 hr. The plates were washed three times with PBS and blocked with 3% (w/v) skim milk in PBS for 1 hr at RT. The blocking buffer was then discarded and 100 mL of 1/10,000 diluted HRP-conjugated anti-His tag antibody in PBS (1:10,000, v/v) (Abcam, Cambridge, UK) added to the wells and incubated at 37°C for 1 hr. After four rounds of washing with TBST, 50 mL of 3,3',5,5'-tetramethylbenzidine ELISA substrate solution (Sigma-Aldrich, St Louis, MO, USA) was added and incubated for 15 min at RT. Finally, 50 mL of 2 M HCL was added to stop the reactions. OD values were determined at 450 nm.
Evaluation of EM-L2 peptide by ELISA
Wells were coated with 1 mg of purified EM-L2 in 100 mLl Na 2 CO 3 /NaHCO 3 buffer and incubated at 4°C overnight. The plates were washed twice with TBST and blocked with 5% (w/v) skim milk in TBST for 1 hr at RT. The blocking buffer was discarded and 1 mg of anti-EGFR antibodies (ICR61, ICR62) (27) and rabbit IgGs against mimotope (17) were added to the wells and incubated for 1 hr at 37°C. The wells were washed five times with PBST, after which 100 mL of 1/10,000 diluted HRP-conjugated secondary antibody in PBS (1:10,000, v/v) (Pharmacia Biotech, Cambridge, UK) was added to the wells and the mixture incubated at 37°C for 1 hr. After five washes with TBST, 50 mL of 3,3',5,5'-tetramethylbenzidine ELISA substrate solution (SigmaAldrich) was added and incubated for 15 min at RT. Finally, 50 mL of 2 M HCL was added to stop the reactions. OD values were determined at 450 nm.
Evaluation of peptide immunogenicity by immunization of BALB/c mice
Four BALB/c female mice, aged 8-12 weeks (Pasteur Institute of Iran, Tehran, Iran), were divided into two groups. The first test group (group EM-L2) was immunized s.c. with 50 mg of EM-L2 in 100 mL PBS/ FA buffer (1:1, v/v) adjuvant, complete for the first immunization and incomplete for the rest (Sigma). The second group (control group) received 50 mg of BSA in 100 mL PBS/FA buffer (1:1, v/v) adjuvant, complete for the first immunization and incomplete for the rest. This was injected s.c. four times at 7-day intervals. The mice were bled 3 days after the last injection. The immunization protocol for the study was approved by the Animal Care and Use Committee of Tehran University of Medical Sciences.
Peptide ELISA of BALB/c mice serum against EM-L2 peptide An ELISA test was performed to evaluate the immunogenicity of the peptide. Wells were coated with 1 mg purified EM-L2 in 100 mL Na 2 CO 3 /NaHCO 3 buffer and incubated at 4°C overnight. The plates were washed twice with TBST and blocked with 5% (w/v) skim milk in TBST for 1 hr at RT. The blocking buffer was then discarded and mice serum added to the wells at three dilutions (1:500, 1:2000 and 1:4000, serum/PBS, v/v) and incubated for 1 hr at 37°C. The test was continued as previously described.
Cell culture and tumor model establishment LL/2 cells (National Cell Bank of Iran, Tehran, Iran) were cultured in DMEM supplemented with 10% (v/v) FBS at 37°C in an atmosphere containing 5% (v/v) CO 2 . At a confluency of 90%, the cells were trypsinized (Biosera, Gentaur, Austria) and washed with sterile PBS. The cells were then counted and resuspended in DMEM media. To establish the tumor, one week after the last booster, about 10 6 cells in 100 mL DMEM media were injected s.c. into the right flanks of the immunized C57BL6/J mice.
Investigation of anti-tumor effects of EM-L2 peptide vaccine in mice
To investigate prophylactic efficacy, three groups each of four mice were created. Groups p-EM-L2, p-BSA and p-PA were injected s.c. with 50 mg of either EM-L2 or BSA in 100 mL PBS/FA (1:1, v/v) adjuvant, complete for the first immunization and incomplete for the rest, once a week for 4 weeks. One week after the last immunization, the mice were challenged s.c. with 10 6 living LL/2 cells. For the therapeutic studies, mice were first challenged by injecting 10 6 living LL/2 cells s.c. into the right flank. When the tumors were palpable, the mice were divided into three groups, each of four. Groups t-EM-L2, t-BSA and t-PA received s.c. injections in the same way as the mice in the prophylactic experiment. Groups p-PA and t-PA received no antigen. The growth rates of animals in both the prophylactic and therapeutic groups were measured three times a week using digital calipers; survival was also documented. Tumor size (V) is expressed as the product of V ¼ 4/3p (R 1 ) 2 (R 2 ), (where R 1 is the largest diameter and R 2 the smallest diameter).
Statistical analysis
Data are expressed as means AESEM. Comparative analyses were performed using Student's t-test. Tumor volumes were appraised by one-way anova followed by Dunnett's multiple comparison tests. P < 0.05 was considered to denote statistical significance. Statistical analysis and production of figures was done uisng Microsoft Office Excel.
RESULTS
Evaluation of EM-L2 peptide by ELISA
Using the sequences for each factor (Table 1) , the EM-L2 peptide (Fig. 1) was designed. The accuracy of the designed antigen was assessed by ELISA using antiHis-tag antibody (Fig. 2a) ICR61, ICR62 , rabbit IgGs against the mimotope and an irrelevant antibody (antiprogesterone) as control (Fig. 2b) . Around 50% OD difference between the test and control groups showed that the recombinant peptide can react toward specific antibodies. The obtained results indicate that the antigen was appropriately expressed, purified and folded. Details of results are shown in Figure 2 .
Evaluation of peptide immunogenicity in BALB/c mice
To evaluate the immunization of BALB/c mice, three different dilutions of mouse serum were pooled (serum/ PBS, v/v) for ELISA. Higher titers of anti-peptide antibody were found after the final booster injection than with control serum. These results indicate that this peptide antigen is capable of overcoming the tolerance problem that is common in immunizations against selfantigens. Details of results are shown in Figure 3 .
Prophylactic effects of the peptide vaccine
To evaluate the prophylactic properties of the EM-L2 peptide, C57BL6/J inbred mice immunized s.c. with the peptide vaccine were challenged s.c. with around 10 6 LL/2 cells. Mice immunized with the recombinant peptide vaccine had smaller tumors and a greater survival rate than did control mice. That is, tumor growth rate differed significantly between the test and control groups (P < 0.05), whereas the difference between the p-BSA and p-P/A groups was not significant (Fig. 4a) . Additionally, the survival rate was greater in the p-EM-L2 group than in the control groups. Survival rates were about 25%, 29% and 48% for the p-P/A, p-BSA and p-EM-L2 groups, respectively (Fig. 4b) .
Therapeutic effects of the peptide vaccine
EM-L2 peptide not only reduced tumor growth in the t-L2Dem group but also resulted in a greater survival rate than in the t-BSA and t-PA groups. There were significant differences in tumor growth and survival rates between the t-EM-L2 and control groups (P < 0.05 (Fig. 5a ), the survival rates being 28%, 32% and 42% for the t-P/A, t-BSA and t-EM-L2 groups, respectively (Fig. 5b) .
DISCUSSION
The role of EGFR as a major receptor in response to the growth activity of EGF makes it a potential target for anti-cancer therapy. Regardless of the distribution of EGFR in an organism, this glycoprotein is considered a tumor-associated antigen because of its over-expression in some epithelial tumors (28) , its inference in tumor growth and its association with a bad prognosis (29) . Various clinical trials are currently using tyrosine kinase inhibitors and MAbs to target this molecule for passive therapy (30) (31) (32) . It is known that the L1 and L2 domains of EGFR are devoted to ligand binding (33) . However, domain L2 appears to contribute most of the binding energy and is more important in EGF binding (34) . Because of its unique features, we selected the L2 domain for peptide design in our study. Because the EGFR molecule is highly abundant in epithelial cells, it is considered to be a weak immunogen. Using carefully designed epitopes along with appropriate fusion moieties is an appealing approach to circumventing the low immunogenicity of EGFR-based vaccine candidates. In the design of an effective cancer vaccine, epitope specificity is of essential importance. The antibody response against a vaccine candidate is polyclonal; thus, some of the elicited antibodies may inhibit tumour growth whereas others may stimulate it (35) . Inclusion of peptide mimotopes (short peptide sequences mimicking epitope structure such as characterized EGFR mimotope) (17) , as tractable means of producing antibodies could directed the immune system towards epitopes with tumour inhibition capability (36) . In view of these facts, we fused L2 domain of EGFR and its mimotope to construct a new peptide vaccine. Our analyses demonstrated that the designed peptide reacts with anti-EGFR and anti-mimotope antibodies, behaving as an efficient vaccine for EGFR þ tumors. The wide distribution of EGFR in normal tissues suggests that this molecule is a poor immunogen. However, it has been demonstrated that the murine EGFR extracellular domain with a suitable adjuvant like FA and Her2 in Detox adjuvant are sufficiently immunogenic in mice and monkeys to promote a strong anti-metastatic effect (37) . In addition to these findings, Disis et al. showed that a part of Her2, but not the whole protein, can be employed as a vaccine candidate (38) . In another study, Sanchez Ramirez et al. showed that VSSP from Neisseria meningitidis can be used as a promising adjuvant for circumventing tolerance to self EGFR (39) and deploying active anti-metastatic immunotherapy. In their subsequent study, they showed that polyclonal antibodies induced by their vaccine formulation containing EGFR and VSSP as novel nano-particulated adjuvant had anti-proliferative and pro-apoptotic effects (40) . EM-L2 peptide was injected into BALB/c mice to evaluate its immunogenicity. The observed 50% OD difference proves the immunogenicity of the peptide. Our results thus show that emulsifying recombinant EM-L2 peptide in FA may be a powerful vaccination strategy. Fig. 3 . EM-L2 peptide immunogenicity assay. One microgram of purified peptide was coated on each well and ELISA performed using three dilutions of BALB/c mice serum (1:500, 1:2000 and 1:4000, serum/PBS, v/v). Group L2D-Em, sera of mice immunized with EM-L2 peptide; control group, sera of mice that received BSA; NI, sera of non-immunized mice. Each bar represents the mean AE SD. Fig. 4 . Prophylactic properties of the EM-L2 peptide vaccine. Mice were challenged by injecting LL/2 cells s.c. one week after the last immunization and the sizes of subsequent tumors measured for four weeks. There were significant differences in (a) tumor size and (b) survival rate between the immunized and control groups, whereas there were no significant differences in tumor growth rate or survival rate between the control groups. Each bar represents the mean AE SD. p-EM-L2, mice immunized s.c. with EM-L2 peptide; p-BSA, mice that received s.c. BSA; p-P/A, mice that received s.c. PBS/FA. P, prophylactic; L2D, L2 domain of EGFR; Em EGFR mimotope.
The LL/2 cell line has been used to establish tumor models in C57BL/6 mice. This cell line forms spontaneously in female C57BL/6 mice and several cell lines, including the LL/2 cell line, have been derived from these tumors (41) . It is well-known that the LL/2 cell line overexpresses EGFR; it has been used repeatedly to establish EGFR þ tumors in previous studies (39, 42, 43) . In investigations of the in vivo anti-tumor effects of the designed vaccine, we observed significant differences in tumor growth rate between the p-EM-L2 and the control groups in the prophylactic and therapeutic mice. There was no significant difference in tumor growth rate between the PA and BSA groups. These results clearly suggest that this novel vaccine candidate has therapeutic and prophylactic potency; however the prophylactic potency of the peptide vaccine was more promising, especially in surveillance evaluation. On Day 45 of the test, the surveillance rates of the p-EM-L2 and t-EM-L2 groups were 50% and 25%, respectively. Xenopus FGFR-1 in the study conducted by Lu et al. and the auto EGFR-ECD protein in the study conducted by Hu et al. have pulsed dendritic cells. These vaccines reportedly kept 60% of mice that had been preventatively injected and afterwards challenged with LL/2c tumor alive (43, 44) . Anti-EGFR mAbs ICR61and ICR62 can block binding of EGF, TGF-a, heparin-binding-EGF and betacellulin to EGFR (27) . Thus, we anticipated that the produced antibodies against EM-L2 would act like ICR61and ICR62 and compete with EGF to bind the EGFR molecule. Autoimmune responses are a possible adverse effect of such self-protein target therapy. Lee et al. reported skin rashes as an adverse effect associated with administration of anti-EGFR drugs (45) ; however, in the majority of related experiments no major toxic effects have been found. Although our study did not specifically investigate toxicities of immunizations, we observed no unusual complications like skin rushes during the mouse experiments.
In conclusion, apart from the obtained results, cancer immunotherapy methods have many advantages over conventional methods. However, more specific investigations should be carried out to optimize immunogenicity against peptide vaccines. We have demonstrated that displaying EM-L2 peptide on phage surfaces may strongly affect immunization potency and improve antibody titers. Therefore, investigations of cancer immunotherapy may open exciting possibilities concerning hyperimmunization, leading to more promising results regarding tumor regression and proliferation. Our findings suggest peptide vaccination may be an attractive approach to active immunotherapy for individuals with cancer.
